Overview

  • Product name
    Anti-VEGFA antibody [6D3]
    See all VEGFA primary antibodies
  • Description
    Mouse monoclonal [6D3] to VEGFA
  • Specificity
    Recognizes vascular endothelial growth factor A precursor (VEGFA).
  • Tested applications
    Suitable for: WB, ELISA, Neutralisingmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Recombinant full length protein corresponding to Human VEGFA.

  • Positive control
    • Recombinant VEGF165.

Properties

Applications

Our Abpromise guarantee covers the use of ab36424 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 2 - 10 µg/ml. Predicted molecular weight: 45 kDa.
ELISA Use a concentration of 1 - 15 µg/ml.
Neutralising Use at an assay dependent dilution. Has been shown to block the VEGFA induced proliferation of ACE cell at a 1:6 molar ratio of ligand to antibody. Inhibits the binding of VEGF A to the VEGF receptors 1 (Flt-1) and 2 (KDR).

Target

  • Function
    Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.
  • Tissue specificity
    Isoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed.
  • Involvement in disease
    Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:603933]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
  • Sequence similarities
    Belongs to the PDGF/VEGF growth factor family.
  • Cellular localization
    Secreted. VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a signicant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.
  • Information by UniProt
  • Database links
  • Alternative names
    • Folliculostellate cell-derived growth factor antibody
    • Glioma-derived endothelial cell mitogen antibody
    • MGC70609 antibody
    • MVCD1 antibody
    • Vascular endothelial growth factor A antibody
    • vascular endothelial growth factor A121 antibody
    • vascular endothelial growth factor A165 antibody
    • vascular endothelial growth factor antibody
    • Vascular permeability factor antibody
    • VEGF A antibody
    • Vegf antibody
    • VEGF-A antibody
    • VEGF120 antibody
    • Vegfa antibody
    • VEGFA_HUMAN antibody
    • VPF antibody
    see all

References

This product has been referenced in:
  • Hudson EP  et al. Multiplex epitope mapping using bacterial surface display reveals both linear and conformational epitopes. Sci Rep 2:706 (2012). Read more (PubMed: 23050090) »
  • Rossi SL  et al. Histological and functional benefit following transplantation of motor neuron progenitors to the injured rat spinal cord. PLoS One 5:e11852 (2010). Blocking ; Human . Read more (PubMed: 20686613) »

See all 2 Publications for this product

Customer reviews and Q&As

Thank you for your reply.

These products were created using full length VEGF recombinant proteins. We are not currently aware of the exact epitopes recognized by the antibodies. I did run alignments of the human VEGF protein to both rat an...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up